| | Identification | Back Directory |  | [Name] 
 Sitagliptin Impurity 21
 |  | [CAS] 
 2088771-60-0
 |  | [Synonyms] 
 2088771-60-0
 Sitagliptin-14
 Sitagliptin FP Impurity A
 Sitagliptin Impurity FP-A
 USPSitagliptinFumarateadduct
 2-(((R)-4-oxo-4-(3-(trifluoromethyl)
 Sitagliptin Tablets EP Impurity FP-A
 Sitagliptin Fumarate Adduct Impurity
 Sitagliptin Fumarate Adduct(Sitagliptin Impurity FP-A)
 (R)-Sitagliptin rac-Fumarate Adduct (mixture of diastereomers)
 Sitagliptin FP Impurity A/ Sitagliptin Fumarate Adduct/ Sitagliptin Maleate Adduct
 ((R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo [4,3-a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-yl) aspartic acid
 2-{[(2R)-4-oxo-4-[3-(trifluoromethyl)-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-1-(2,4,5-trifluorophenyl)butan-2-yl]amino}butanedioic acid
 L-Aspartic acid, N-[(1R)-3-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-3-oxo-1-[(2,4,5-trifluorophenyl)methyl]propyl]-
 Sitagliptin impurity 5/Sitagliptin FP Impurity A/Sitagliptin Fumarate Adduct/Sitagliptin Maleate Adduct/N-[(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-yl]aspartic acid
 |  | [Molecular Formula] 
 C20H19F6N5O5
 |  | [MDL Number] 
 MFCD33550932
 |  | [MOL File] 
 2088771-60-0.mol
 |  | [Molecular Weight] 
 523.39
 | 
 | Chemical Properties | Back Directory |  | [Melting point ] 
 149 - 153°C
 |  | [Boiling point ] 
 673.9±65.0 °C(Predicted)
 |  | [density ] 
 1.66±0.1 g/cm3(Predicted)
 |  | [storage temp. ] 
 Hygroscopic, -20°C Freezer, Under inert atmosphere
 |  | [solubility ] 
 DMSO (Slightly), Methanol (Slightly)
 |  | [form ] 
 Solid
 |  | [pka] 
 2.05±0.23(Predicted)
 |  | [color ] 
 White to Off-White
 |  | [InChIKey] 
 SDIOBAOATSWLLA-YGRLFVJLSA-N
 |  | [SMILES] 
 C(O)(=O)[C@H](CC(O)=O)N[C@H](CC1=CC(F)=C(F)C=C1F)CC(N1CCN2C(C(F)(F)F)=NN=C2C1)=O
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 Sitagliptin Fumarate Adduct is an impurity of Sitagliptin (S491000), a trizolopyrazine dipeptidyl peptidase IV inhibitor. Sitagliptin has recently been approved for the therapy of type II diabetes.
 | 
 | 
                    
                        
                            | Company Name: | LANSPHARMA |  
                            | Tel: | +91-9000766909 |  
                            | Website: | www.lanspharma.com |  |